cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
United Therapeutics Corporation
17 own
15 watching
Current Price
$237.93
$1
(0.42%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
11,927.01M
52-Week High
52-Week High
261.54001
52-Week Low
52-Week Low
204.44000
Average Volume
Average Volume
0.36M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
20.825
iconMarket Capitalization11,927.01M
icon52-Week High261.54001
icon52-Week Low204.44000
iconAverage Volume0.36M
iconDividend Yield--
iconP/E Ratio20.825
What does the United Therapeutics Corporation do?
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More
How much money does United Therapeutics Corporation make?
News & Events about United Therapeutics Corporation.
Ticker Report
1 year ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the sale, the ...
Zolmax
1 year ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the stock in a transaction dated Friday, February 24th. The stock was sold at an average price of $249.27, for a total transaction of $1,994,160.00. Following the transaction, the chief executive officer ...
Zolmax
1 year ago
Shares of United Therapeutics Co. (NASDAQ:UTHR Get Rating) have been given an average rating of Moderate Buy by the thirteen analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating on the ...
Zolmax
1 year ago
Shares of United Therapeutics Co. (NASDAQ:UTHR Get Rating) have received an average rating of Moderate Buy from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eight have given a buy rating and one ...
Ticker Report
1 year ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the companys stock in a transaction on Friday, January 27th. The stock was sold at an average price of $260.01, for a total transaction of $2,080,080.00. Following the completion of the ...
Frequently Asked Questions
Frequently Asked Questions
What is United Therapeutics Corporation share price today?
plus_minus_icon
Can Indians buy United Therapeutics Corporation shares?
plus_minus_icon
How can I buy United Therapeutics Corporation shares from India?
plus_minus_icon
Can Fractional shares of United Therapeutics Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in United Therapeutics Corporation stocks?
plus_minus_icon
What is today’s traded volume of United Therapeutics Corporation?
plus_minus_icon
What is today’s market capitalisation of United Therapeutics Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of United Therapeutics Corporation?
plus_minus_icon
What percentage is United Therapeutics Corporation down from its 52-Week High?
plus_minus_icon
What percentage is United Therapeutics Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$237.93
$1
(0.42%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00